Llombart-Cussac, A.; Anton-Torres, A.; Rojas, B.; Andrés, R.; Martinez, N.; RodrÃguez, C.A.; Marin, S.; Puértolas, T.; González, A.F.; Fernández-Murga, M.L.;
et al. Impact of the 21-Gene Assay in Patients with High-Clinical Risk ER-Positive and HER2-Negative Early Breast Cancer: Results of the KARMA Dx Study. Cancers 2023, 15, 1529.
https://doi.org/10.3390/cancers15051529
AMA Style
Llombart-Cussac A, Anton-Torres A, Rojas B, Andrés R, Martinez N, RodrÃguez CA, Marin S, Puértolas T, González AF, Fernández-Murga ML,
et al. Impact of the 21-Gene Assay in Patients with High-Clinical Risk ER-Positive and HER2-Negative Early Breast Cancer: Results of the KARMA Dx Study. Cancers. 2023; 15(5):1529.
https://doi.org/10.3390/cancers15051529
Chicago/Turabian Style
Llombart-Cussac, Antonio, Antonio Anton-Torres, Beatriz Rojas, Raquel Andrés, Noelia Martinez, César A. RodrÃguez, Sara Marin, Teresa Puértolas, Alejandro Falcón González, MarÃa Leonor Fernández-Murga,
and et al. 2023. "Impact of the 21-Gene Assay in Patients with High-Clinical Risk ER-Positive and HER2-Negative Early Breast Cancer: Results of the KARMA Dx Study" Cancers 15, no. 5: 1529.
https://doi.org/10.3390/cancers15051529
APA Style
Llombart-Cussac, A., Anton-Torres, A., Rojas, B., Andrés, R., Martinez, N., RodrÃguez, C. A., Marin, S., Puértolas, T., González, A. F., Fernández-Murga, M. L., Hagen, C., & Ruiz-Borrego, M.
(2023). Impact of the 21-Gene Assay in Patients with High-Clinical Risk ER-Positive and HER2-Negative Early Breast Cancer: Results of the KARMA Dx Study. Cancers, 15(5), 1529.
https://doi.org/10.3390/cancers15051529
